N/A N=120 Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c — 7.99; 7.69; 7.69; 7.58 percentage of glycated hemoglobin — p==0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
Attention Deficit Hyperactivity Disorder · Autism Spectrum Disorder · Pervasive Developmental Disorder
Primary: Number of Participants With an Increase/Improvement in Focusing — 6 participants
Phase 2 N=58 Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Acute Myocardial Infarction
Primary: Change in Left Ventricular End-Systolic Volume Index — -2.1; -4.6 mL of blood/meter^2 body surface area — p=0.97
N/A N=25 Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Schizophrenia
Primary: Overnight Change on Finger Tapping Task — 21; 2 percent change
Phase 3 N=123 A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Parkinson's Disease Psychosis
Primary: Antipsychotic Efficacy — -4.4; NA; -6.5; NA Scores on the SAPS H+D scale
N/A N=20 Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy
Diabetes Mellitus, Type 1
Primary: Safety, Low Blood Glucose Index (LBGI) — 0.64; 1.12 index score — p=0.003
Phase 3 N=374 Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
Male Subjects With Chronic Constipation
Primary: The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week — 17.7; 37.9 percentage of subjects — p=<0.0001
Phase 2 N=91 A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790
Phase 2 N=14 SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Phase I Maximum Tolerated Dose (MTD) of Vorinostat — 300 mg/day
Phase 3 N=26 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Nonalcoholic Steatohepatitis · Liver Diseases
Primary: The Number of Participants With a 30% Reduction in Alanine Aminotransferase (ALT) Treated With Pentoxifylline (PTX) or Placebo for 12 Months. — 19; 7 participants — p=0.46
Phase 2 N=335 Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
Asthma
Primary: Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85) — 2.190; 2.216; 2.110 Liters
Phase 3 N=566 Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening
Colorectal Cancer
Primary: Colorectal Cancer (CRC) Screening Completion — 17; 69 participants — p=0.32
Phase 3 N=406 Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 2 N=101 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Central Nervous System Tumor, Pediatric · Leukemia · Lymphoma
Primary: Therapy Completion Rate — .25 proportion of patients
Phase 2 N=221 DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
Diabetic Macular Edema
Primary: Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) — 2.5; 8.6; 11.4; 8.5 letters correctly read